Evidence map›Paper›PMID 40674145›Full record

ArticleThe Journal of clinical investigation2025

Aggressive B cell lymphomas retain ATR-dependent determinants of T cell exclusion from the germinal center dark zone.

Valeria Cancila, Giorgio Bertolazzi, Allison Sy Chan, Giovanni Medico, Giulia Bastianello, Gaia Morello, Daniel Paysan, Clemence Lai, Liang Hong, Girija Shenoy and 39 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

49 authors.

Valeria CancilaTumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy.
Giorgio BertolazziDepartment of Medicine and Surgery, Kore University of Enna, Enna, Italy.
Allison Sy ChanCancer Science Institute of Singapore, National University of Singapore, Singapore.
Giovanni MedicoTumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy.
Giulia BastianelloGenome Integrity Lab, IFOM ETS-The Italian Association for Cancer Research (AIRC) Institute of Molecular Oncology, Milan, Italy.
Gaia MorelloTumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy.
Daniel PaysanLaboratory for Nanoscale Biology, Paul Scherrer Institute, Villigen, Switzerland.
Clemence LaiCancer Science Institute of Singapore, National University of Singapore, Singapore.
Liang HongCancer Science Institute of Singapore, National University of Singapore, Singapore.
Girija ShenoyCancer Science Institute of Singapore, National University of Singapore, Singapore.
Patrick W JaynesCancer Science Institute of Singapore, National University of Singapore, Singapore.
Giovanna SchiavoniDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Fabrizio MatteiDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Silvia PiconeseDepartment of Internal Clinical Sciences, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
Maria V RevueltaDivision of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York, USA.
Francesco NotoDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Luca BusinaroInstitute for Photonics and Nanotechnologies, Italian National Research Council, Rome, Italy.
Adele De NinnoInstitute for Photonics and Nanotechnologies, Italian National Research Council, Rome, Italy.
Ilenia CammarataDepartment of Translational and Precision Medicine, Sapienza University of Rome, Neuroimmunology Unit, IRCCS Fondazione Santa Lucia, Rome, Italy.
Fabio PagniDepartment of Medicine and Surgery, Pathology, IRCCS Fondazione San Gerardo dei Tintori, University of Milano-Bicocca, Milan, Italy.
Saradha VenkatachalapathyLaboratory for Nanoscale Biology, Paul Scherrer Institute, Villigen, Switzerland.
Sabina SangalettiMolecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Arianna Di NapoliPathology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
Giada CicioAdvanced Pathology Laboratory, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy.
Davide VaccaTumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy.
Silvia LonardiPathology Unit, ASST Spedali Civili di Brescia, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Luisa LorenziPathology Unit, ASST Spedali Civili di Brescia, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Andrés Jm FerreriLymphoma Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Beatrice BelmonteTumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy.
Min LiuCancer Science Institute of Singapore, National University of Singapore, Singapore.
Manikandan LakshmananInstitute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore.
Michelle Sn OngInstitute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore.
Biyan ZhangSingapore Immunology Network, A*STAR, Singapore.
Tingyi SeeSingapore Immunology Network, A*STAR, Singapore.
Kong-Peng LamSingapore Immunology Network, A*STAR, Singapore.
Gabriele VaranoGenetics of B Cells and Lymphoma Unit, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy.
Mario P ColomboMolecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Silvio BicciatoDepartment of Molecular Medicine, University of Padova, Padova, Italy.
Giorgio InghiramiDivision of Hematopathology, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York, USA.
Leandro CerchiettiDivision of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York, USA.
Maurilio PonzoniVita-Salute San Raffaele University, Milan, Italy.
Roberta ZappasodiDepartment of Medicine, Weill Cornell Medicine, New York, New York, USA.
Evelyn MetzgerBruker Spatial Biology, Seattle, Washington, USA.
Joseph BeechemBruker Spatial Biology, Seattle, Washington, USA.
Fabio FacchettiPathology Unit, ASST Spedali Civili di Brescia, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Marco FoianiGenome Integrity Lab, IFOM ETS-The Italian Association for Cancer Research (AIRC) Institute of Molecular Oncology, Milan, Italy.
Stefano CasolaGenetics of B Cells and Lymphoma Unit, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy.
Anand D JeyasekharanCancer Science Institute of Singapore, National University of Singapore, Singapore.
Claudio TripodoTumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy.

Funding

Project 4 Green-DavisP01CA272295 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Leandro C Cerchietti, CHRISTOPHER R FLOWERS · 2024 to 2026
$9.3M
Role of the stromal microenvironment in B-cell lymphoma progression and immune escapeR01CA242069 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CERCHIETTI, LEANDRO C · 2020 to 2024
$2.9M
NCI NIH HHS P01 CA272295NCI NIH HHS R01 CA242069
6 · The paper itself

Abstract

The germinal center (GC) dark zone (DZ) and light zone represent distinct anatomical regions in lymphoid tissue where B cell proliferation, immunoglobulin diversification, and selection are coordinated. Diffuse large B cell lymphomas (DLBCLs) with DZ-like gene expression profiles exhibit poor outcomes, though the reasons are unclear and are not directly related to proliferation. Physiological DZs exhibit an exclusion of T cells, prompting exploration of whether T cell paucity contributes to DZ-like DLBCL. We used spatial transcriptomic approaches to achieve higher resolution of T cell spatial heterogeneity in the GC and to derive potential pathways that underlie T cell exclusion. We showed that T cell exclusion from the DZ was linked to DNA damage response (DDR) and chromatin compaction molecular features characterizing the spatial DZ signature, and that these programs were independent of activation-induced cytidine deaminase (AID) activity. As ATR is a key regulator of DDR, we tested its role in the T cell inhibitory DZ transcriptional imprint. ATR inhibition reversed not only the DZ transcriptional signature, but also DZ T cell exclusion in DZ-like DLBCL in vitro microfluidic models and in in vivo samples of murine lymphoid tissue. These findings highlight that ATR activity underpins a physiological scenario of immune silencing. ATR inhibition may reverse the immune-silent state and enhance T cell-based immunotherapy in aggressive lymphomas with GC DZ-like characteristics.

Indexed as

Ataxia Telangiectasia Mutated ProteinsGerminal CenterLymphoma, Large B-Cell, DiffuseNeoplasm ProteinsT-LymphocytesAnimalsCell Line, TumorCytidine DeaminaseDNA DamageHumansMiceAtaxia Telangiectasia Mutated ProteinsATR protein, humanCytidine DeaminaseNeoplasm ProteinsCell biologyImmunologyLymphomasMolecular pathologyOncologyT cells

Identifiers

PMID40674145
PMCPMC12435852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.